Browsing the "CASMI Views" Category

Uncertainty: The Key to Health Leadership

policy and impact_slider

As always at this point in the political cycle, there is a great deal of uncertainty about future policy directions, funding sources and the longevity of certain programmes. Uncertainty has a habit of making people feel anxious, insecure and stressed.  It is often cited anecdotally – personally, the uncertainty over [...]

February 5, 2015 Andrea Hodgetts CASMI Views 0

Reflections on a Health Crisis

non-slider CASMI_graphic_6

Ebola is worrying, very worrying. The worst outbreak of recent times has taken thousands of lives in four West African countries and the virus has begun to appear in the US and Europe – and in one case transmitted to a local healthcare worker. The death rate from this terrible [...]

October 13, 2014 Andrea Hodgetts CASMI Views 0

How to Succeed at Open Innovation – Rosie Pigott’s Blog for Wellcome Trust

slider CASMI_graphic_10

Blog repost from the Wellcome Trust. Read the original article here Today we launch “Shaping the Future of Open Innovation: A practical guide for life sciences organisations”, a new resource created by a collaboration led by the Wellcome Trust, the Centre for the Advancement of Sustainable Medical Innovation (CASMI) and Kinapse.Rosie Pigott from CASMI, [...]

September 4, 2014 Andrea Hodgetts CASMI Views 0

“We are gradually going to move away from fully fledged HTAs towards more European collaboration.”

richard Bergstrom

National associations throughout Europe are engaging with governments in a whole new way. At a recent Eyeforpharma event, Richard Bergstrom, Director General of EFPIA, spoke about: – How the regulatory model is changing – The benefits of sharing expectations and the strengths and weaknesses of company data with regulators, payers and patients [...]

August 13, 2014 Andrea Hodgetts CASMI Views 0

Putting Patients at the Heart of Medical Innovation


It’s time that we truly put patients at the heart of medical innovation. When I say that, I don’t mean adding a token patient to a conference speaker panel or ‘box ticking’ that a pharmaceutical company has consulted a patient group. What I mean is that we need to completely [...]

June 10, 2014 Andrea Hodgetts CASMI Views 0

CASMI Fellow Speaks about ‘Patient Participation in Melanoma Clinical Research’

144 09 070 RNTNEH Prof Shak Sayeed 1407_WEB_edit

CASMI Associate Fellow Dr Sarah Garner spoke at the Joint M-icab/ESO Conference in Brussels last weekend. Upon a joint invitation from m-icab, (Melanoma Independent Community Advisory Board), and ESO, (European School of Oncology) about 90 stakeholders – Melanoma patients and advocates, clinicians, representatives from the regulatory and Health Technology Assessment [...]

April 4, 2014 Andrea Hodgetts CASMI Views 0

Podcast: Reaching a Personalized Medicine Milestone

non-slider CASMI_graphic_9

With the recent news that Illumina’s latest sequencers have broken the $1,000 genome barrier, there’s great anticipation about the acceleration of personalized medicine. The Burrill Report spoke to Ed Abrahams, president of the Personalized Medicine Coalition, about the significance of the milestone, the move of whole genome sequencing to the [...]

February 4, 2014 Andrea Hodgetts CASMI Views 0

Tufts study: Data suggest breakthrough therapy designation meets goals


Nearly 18 months after its launch by the FDA, the breakthrough therapy designation (BTD) is showing the potential to meet the agency’s stated goal of speeding the development and review of drugs that show early evidence of offering substantial improvement over existing therapies on a clinically significant endpoint. By approving [...]

February 4, 2014 Andrea Hodgetts CASMI Views 0

Podcast: Pharma Faces Shrinking Returns from Innovation

burril report

The biggest pharmaceutical companies are successfully bringing new products to market, but are struggling with diminishing returns on investment, according to a new report from Deloitte and Thomson Reuters. The Burrill Report spoke to Neil Lesser, principal of life sciences strategy for Deloitte, about the industry’s efforts to remake R&D, [...]

December 11, 2013 Andrea Hodgetts CASMI Views 0

FDA on Personalised Medicine

BioCentuary Personalised Medicine

Stratified Medicine (personalising treatments to distinct patient populations) is the topic of this week’s BioCentury videocast. The FDA recently approved Illumina’s Next Generation Sequencing Technology, which rapidly and affordably sequences a patient’s genome, allowing doctors to make tailored treatment decisions after a single test. Following this decision, FDA Commissioner Margaret [...]

November 25, 2013 Andrea Hodgetts CASMI Views 0